Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiesi Farmaceutici S.p.A.

https://www.chiesi.com/en/

Latest From Chiesi Farmaceutici S.p.A.

NVIDIA Extends Its Biopharma Tentacles

NVIDIA is further embedding itself in the biopharma industry. Its artificial intelligence tools are now more accessible, integrated and it is taking a strategic collaborative approach with competitors like Google to bolster AI-driven startups that ultimately use its tools. 

Artificial Intelligence Innovation

Quantum Outperforms Classical Computer, Finding New KRAS Inhibitors

In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.

Innovation Artificial Intelligence

Moeller Looks To Prove BenevolentAI’s Doubters Wrong

The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.

Companies Artificial Intelligence

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Cornerstone Therapeutics (Cardiokine, Inc.
    • Critical Therapeutics, Inc.
    • EKR Therapeutics Inc.)
    • Torrex Chiesi Pharma
    • Zymenex Holding A/S
    • Atopix Therapeutics Limited
UsernamePublicRestriction

Register